Super-fast-acting Prandial Insulin Product Receives £0.5m Innovate UK Boost

Super-fast product addresses critical unmet need in development of next generation artificial pancreas systems” “Novel formulation significantly accelerates absorption of insulin post injection – accelerating the onset of glucose lowering.” Cambridge, UK., 13 February 2019: Arecor Ltd (“the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for […]

How Forward Thinking and New Approaches Will Drive Up Efficiency

Charlie Johnson, CEO of  biotechnology company ADC Bio, explains how substantial cost savings and faster time to market is achievable through the novel concept of combining the bioconjugation and purification steps. Charlie Johnson – CEO, ADC Bio As an advanced manufacturing concept, integrated bioconjugation is highly promising – and is now under development – with the […]

Data Published in the Journal of Parkinson’s Disease Demonstrate Real-World Clinical Benefit of Global Kinetics’ Personal KinetiGraph® in Optimizing Parkinson’s Disease Therapy

– Additional monitoring data helped clinicians optimize drug therapy in nearly onethird of study patients – PORTSMOUTH, NH USA, LONDON, UK, MELBOURNE, Australia, and MOUNTAIN VIEW, CA USA February 4, 2019 – Global Kinetics Corporation Ltd., in conjunction with the Parkinson’s Institute and Clinical Center, today announced the publication of a joint study in the […]

MS Clinical Trial starting at East Kent

Rex Bionics is the pioneer of the REX® robotic rehabilitation device that provides standing, walking and exercise support for people with lower limb weakness or paralysis; and is used by people who have suffered a spinal cord injury, stroke, traumatic brain injury or other neurological condition such as multiple sclerosis. Rex Bionics has worked with physiotherapists […]

AVITA Medical Second Quarter Fiscal 2019 Quarterly Cash Flow Report and Company Update

Recent Highlights • Pre-launch U.S. product sales of A$1.1 million in second quarter • Successful preparation for U.S. national market launch in January 2019 • 26 abstracts highlighting RECELL® System clinical and economic benefits accepted for presentation at multiple burn conferences, including the American Burn Association (ABA) 51st Annual Meeting • A$41.7 million equity financing […]

SeaDragon Limited announces Director changes

SeaDragon Limited (NZX:SEA) today announces the appointment of Bryan Mogridge to the Board of Directors, with effect from the 1st of February 2019. Bryan has a BSc in Bio-chemistry and was instrumental in building a solid export base for New Zealand wine.  In 1998 he was made an Officer of the New Zealand Order of […]

Second positive phase 1 trial data for XF-73

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.  Destiny Pharma plc (“Destiny Pharma” or “the Company”)  Second positive […]

AVITA Medical Announces Nine RECELL® System Abstracts Accepted for Presentation at American Burn Association (ABA) 51st Annual Meeting

RECELL System clinical benefits and cost savings featured in 26 presentations at four burn conferences in early 2019 Valencia, Calif., USA, and Melbourne, Australia, 29 January 2019 — AVITA Medical (ASX: AVH, OTCQX:AVMXY), a global regenerative medicine company,today announced that 26 abstracts highlighting theclinical and cost savings benefits of the RECELL® Autologous Cell Harvesting Device […]

Destiny Pharma awarded significant new grant funding up to £1.6 million under new UK-China AMR programme

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma […]

Destiny Pharma notes UK 5-year action plan on AMR

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma notes release of UK Government’s Vision and 5-year action plan to help tackle anti-microbial resistance (AMR), which includes additional investment in innovation Government’s plan consistent with Destiny Pharma’s objective of developing novel anti-infectives from its proprietary XF platform. Brighton, United Kingdom – 24 January 2019 – Destiny Pharma (AIM: […]